A research team from the University of Virginia and Stanford University has published innovative preclinical research for treating neurological disorders in the Journal of Neurosurgery.
Their treatment method called “precise intracerebral noninvasive guided (PING) surgery” uses MR-guided, low-intensity focused ultrasound plus microbubbles to open the blood-brain barrier and deliver a neurotoxin to a targeted area of the brain.
The Foundation and the American Institute of Ultrasound in Medicine partnered to host "Focused Ultrasound for the Pediatric and Young Adult Population."
Lauren Powlovich, MD, the Foundation's associate chief medical officer, presented.
An international clinical trial is investigating the use of focused ultrasound on an alternative target in the brain to treat the motor symptoms of Parkinson’s disease.
In the bilateral trial, participants will be evaluated for treatment on the other side of the brain six months after initial treatment.
Sites in Maryland, New York, California, and Taiwan are now seeking patients.
Researchers in Taiwan published data from a small pilot clinical trial testing the use of focused ultrasound neuromodulation in patients with drug-resistant epilepsy.
Participants received low-intensity focused ultrasound in the seizure origination zone from the NaviFUS neuronavigation-guided system.
FUSMobile, a company developing a focused ultrasound platform for neural tissue ablation has published results from its first clinical trial for the treatment of low back pain.
The study enrolled 10 participants, who reported no significant device- or procedure-related adverse events.
The American Society for Radiation Oncology (ASTRO) Annual Meeting was held in Chicago October 24-27.
A presentation by Hong-Jian Wei, PhD, on blood-brain barrier opening for diffuse intrinsic pontine glioma (DIPG) won a Basic/Translational Science Award.
The UNITE initiative aims to identify and address structural racism within the National Institutes of Health (NIH)-supported community and beyond.
Key stakeholders within the biomedical research community are invited to share their insights in a series of listening sessions over the next few months.
Lawmakers have formally introduced the Cures 2.0 bill.
Noteworthy in the legislation is improved communication between the FDA and Medicare and a Medicare reimbursement pathway for breakthrough devices.
The Foundation supports the Cures 2.0 bill, understands its potential impact on the community, and encourages collective advocacy in order to see it become a law.
